Light chain amyloidosis: the heart of the problem.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

50 citing papers in PubMed.

1. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.Blood · 2017
   Trial
2. Myocardial work in light-chain and transthyretin-related amyloidosis with preserved ejection fraction: a cardiovascular magnetic resonance study.Insights into imaging · 2026
   Article
3. Exploring the MicroRNA Landscape in Cardiac Amyloidosis: Molecular Insights and Clinical Applications.Genes · 2026
   Review
4. Bridging the Gap in AL and ATTR Cardiac Amyloidosis: Integrating Histopathology, Biomarkers, and Multimodal Imaging for Subtype-Specific Diagnosis.Reviews in cardiovascular medicine · 2026
   Review
5. Development of an artificial intelligence-based early diagnostic system for light-chain amyloidosis.Annals of hematology · 2025
   Article
6. Improvement in global longitudinal strain following plasma cell-directed therapy is associated with long-term survival among patients with AL amyloidosis.European heart journal open · 2025
   Article
7. A Rare Case of Tracheal Amyloidosis in a Middle-Aged Person.Cureus · 2025
   Article
8. Development and validation of an early prediction model for cardiac death risk in patients with light chain amyloidosis: a multicenter study.Cardio-oncology (London, England) · 2025
   Article
9. Echocardiographic Features of Wild-Type Transthyretin Cardiac Amyloidosis From J-Case: Multicenter Survey in Japan.JACC. Asia · 2025
   Article
10. The myocardial function index (MFI): An integrated measure of cardiac function in AL-cardiomyopathy.International journal of cardiology. Heart & vasculature · 2024
    Article
11. Prognostic Value of Left Ventricular Myocardial Strain Parameters Derived from Cardiac Magnetic Resonance Feature Tracking Technique in Light-Chain Cardiac Amyloidosis Patients: A Pilot Study.Reviews in cardiovascular medicine · 2024
    Article
12. Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis.Nature communications · 2024
    Article
13. Management of tracheobronchial amyloidosis: a review of the literature.ERJ open research · 2024
    Article
14. Advance of echocardiography in cardiac amyloidosis.Heart failure reviews · 2023
    Review
15. Prognosis prediction in cardiac amyloidosis by cardiac magnetic resonance imaging: a systematic review with meta-analysis.European heart journal open · 2023
    Review
16. Current Status of Radionuclide Imaging of Transthyretin Cardiac Amyloidosis.Cardiology clinics · 2023
    Review
17. Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report.World journal of clinical cases · 2022
    Article
18. Noninvasive Diagnostics of Renal Amyloidosis: Current State and Perspectives.International journal of molecular sciences · 2022
    Review
19. A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan.Scientific reports · 2022
    Article
20. Evaluation of a new ELISA assay for monoclonal free-light chain detection in patients with cardiac amyloidosis.EJHaem · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as